Results 21 to 30 of about 1,582,509 (353)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

The Lancet, 2021
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials.
D. Logunov, I. Dolzhikova, D. Shcheblyakov, A. Tukhvatulin, O. Zubkova, A. Dzharullaeva, A. Kovyrshina, N. Lubenets, D. Grousova, A. Erokhova, A. G. Botikov, F. Izhaeva, O. Popova, T. Ozharovskaya, I. Esmagambetov, I. Favorskaya, D. Zrelkin, Daria V Voronina, D. Shcherbinin, A. Semikhin, Y. Simakova, E. Tokarskaya, D. Egorova, M. M. Shmarov, N. Nikitenko, V. Gushchin, E. Smolyarchuk, S. K. Zyryanov, S. Borisevich, B. Naroditsky, A. Gintsburg   +30 more
semanticscholar   +1 more source

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Nature, 2021
Here we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer–BioNTech (BNT162b2) vaccine against SARS-CoV-21–4. Eight weeks after the second injection of vaccine, volunteers showed
Zijun Wang, F. Schmidt, Y. Weisblum, Frauke Muecksch, C. Barnes, Shlomo Finkin, Dennis J. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. Lieberman, Thiago Y. Oliveira, Zhi Yang, M. Abernathy, Kathryn E. Huey-Tubman, A. Hurley, Martina Turroja, K. West, Kristie M Gordon, Katrina G. Millard, Victor Ramos, Justin Da Silva, Jianliang Xu, R. Colbert, R. Patel, Juan P Dizon, Cecille Unson-O’Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P. Bjorkman, R. Casellas, T. Hatziioannou, P. Bieniasz, M. Nussenzweig   +33 more
semanticscholar   +1 more source

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

New England Journal of Medicine, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.
E. Walsh, R. Frenck, A. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, M. Mulligan, R. Bailey, K. Swanson, Ping Li, K. Koury, W. Kalina, David Cooper, Camila R. Fontes-Garfias, P. Shi, Ö. Türeci, Kristin Tompkins, Kirsten E. Lyke, V. Raabe, P. Dormitzer, K. Jansen, U. Şahin, W. Gruber   +24 more
semanticscholar   +1 more source

Emerging concepts in the science of vaccine adjuvants

Nature reviews. Drug discovery, 2021
Adjuvants are vaccine components that enhance the magnitude, breadth and durability of the immune response. Following its introduction in the 1920s, alum remained the only adjuvant licensed for human use for the next 70 years.
B. Pulendran, P. Arunachalam, D. O’hagan   +2 more
semanticscholar   +1 more source

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

New England Journal of Medicine, 2021
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein.
Stephen J. Thomas, E. Moreira, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, F. Polack, C. Zerbini, R. Bailey, K. Swanson, Xia Xu, Satrajit Roychoudhury, K. Koury, S. Bouguermouh, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Qi Yang, P. Liberator, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, W. Gruber, K. Jansen   +31 more
semanticscholar   +1 more source

Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus

, 2021
Conjugation of carbohydrate antigens with a carrier protein is a clinically proven strategy to overcome the poor immunogenicity of bacterial polysaccharide.
조상래
core   +1 more source

VACCINATION. [PDF]

The Lancet
n ...
  +18 more sources

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches

Human Vaccines & Immunotherapeutics, 2022
Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after ...
Judith Absalon, Raphael Simon, David Radley, Peter C. Giardina, Kenneth Koury, Kathrin U. Jansen, Annaliesa S. Anderson   +6 more
doaj   +1 more source

Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops

, 2023
Mucosal vaccines have the advantages of ease of administration and the induction of strong mucosal immunity and a systemic immune response. Recently, the eye mucosa has been shown to be an effective and safe alternative vaccination route against ...
윤상철, 서경률, 이지혜
core   +1 more source

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

Nature Communications, 2021
Identifying and understanding COVID-19 vaccine hesitancy within distinct populations may aid future public health messaging. Using nationally representative data from the general adult populations of Ireland (N = 1041) and the United Kingdom (UK; N ...
J. Murphy, F. Vallières, R. Bentall, M. Shevlin, O. McBride, T. Hartman, Ryan T. McKay, K. Bennett, L. Mason, J. Gibson-Miller, L. Levita, Antón P. Martínez, T. Stocks, T. Karatzias, P. Hyland   +14 more
semanticscholar   +1 more source